Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Rakuten Medical Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution suggests that the company is pursuing multiple distinct technological threads or applications within the biotechnology sector.
The busiest examiner for the company is PERREIRA, MELISSA JEAN, who is responsible for 2 pending office actions. Because this examiner handles the majority of the company's current workload, her examination patterns will significantly influence the overall success rate of the pending biotechnology applications. The remaining workload is handled by another examiner, requiring the applicant to manage different sets of examiner expectations.
With 2 distinct art units involved, the company must ensure its prosecution strategy is adaptable to the specific nuances of each unit. The 3 pending office actions represent the current workload that requires coordination to ensure consistent messaging across the various examiners while addressing the specific technical challenges of the Biotechnology & Pharmaceuticals area. Managing these matters effectively requires a balance between examiner-specific tactics and broad portfolio goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERREIRA, MELISSA JEAN | 2 | 52.0% | +25.8% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17469804 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | PERREIRA, MELISSA JEAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17477419 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | PERREIRA, MELISSA JEAN | 58d overdue |
| 17782111 | METHODS FOR ENHANCING IMMUNITY AND TUMOR TREATMENT | BUTTICE, AUDREY L | — |
| 17632756 | CETUXIMAB-IR700 CONJUGATE COMPOSITIONS | MIDDLETON, DANAYA L | — |
| 17469804 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | PERREIRA, MELISSA JEAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17782111 | METHODS FOR ENHANCING IMMUNITY AND TUMOR TREATMENT | BUTTICE, AUDREY L | 1647 | §103Other | Final Rejection | — | Pending | Jun 02, 2022 |
| 17632756 | CETUXIMAB-IR700 CONJUGATE COMPOSITIONS | MIDDLETON, DANAYA L | 1674 | §112 | Non-Final OA | — | Pending | Feb 03, 2022 |
| 17477419 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | PERREIRA, MELISSA JEAN | 1618 | §103Other | Final Rejection | 58d overdue | Pending | Sep 16, 2021 |
| 17469804 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | PERREIRA, MELISSA JEAN | 1618 | §103§112 | Non-Final OA | — | Pending | Sep 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial